Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 77.36M.
Subavaliada
O PE mais recente da empresa é -7.77, em uma faixa percentil baixa de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 27.85M ações, um aumento de 3.28% em relação ao trimestre anterior.
Mantido por ETHSX
O Super Investidor ETHSX possui 89.47K ações desta empresa.
Baixa Atividade de Mercado
A empresa tem menor interesse dos investidores, com uma taxa de giro de 20 dias de -0.15.